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ABSTRACT
Background
Malaysia’s stable health care system is facing challenges with increasing medicine costs. To
investigate these issues a survey was carried out to evaluate medicine prices, availability,
affordability, and the structure of price components.
Methods and Findings
The methodology developed by the World Health Organization (WHO) and Health Action
International (HAI) was used. Price and availability data for 48 medicines was collected from 20
public sector facilities, 32 private sector retail pharmacies and 20 dispensing doctors in four
geographical regions of West Malaysia. Medicine prices were compared with international
reference prices (IRPs) to obtain a median price ratio. The daily wage of the lowest paid
unskilled government worker was used to gauge the affordability of medicines. Price
component data were collected throughout the supply chain, and markups, taxes, and other
distribution costs were identified. In private pharmacies, innovator brand (IB) prices were 16
times higher than the IRPs, while generics were 6.6 times higher. In dispensing doctor clinics,
the figures were 15 times higher for innovator brands and 7.5 for generics. Dispensing doctors
applied high markups of 50%–76% for IBs, and up to 316% for generics. Retail pharmacy
markups were also high—25%–38% and 100%–140% for IBs and generics, respectively. In the
public sector, where medicines are free, availability was low even for medicines on the National
Essential Drugs List. For a month’s treatment for peptic ulcer disease and hypertension people
have to pay about a week’s wages in the private sector.
Conclusions
The free market by definition does not control medicine prices, necessitating price
monitoring and control mechanisms. Markups for generic products are greater than for IBs.
Reducing the base price without controlling markups may increase profits for retailers and
dispensing doctors without reducing the price paid by end users. To increase access and
affordability, promotion of generic medicines and improved availability of medicines in the
public sector are required.
The Editors’ Summary of this article follows the references.
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The price of medicine is considered one of the most
important obstacles to access [1]. The purchase of medicines
contributes signiﬁcantly to the health care budget of
developing countries, and drug expenditures may amount
to 50%–90% of nonpersonnel costs [2]. In developing
countries, studies and data on medicine prices are scanty.
Measuring and understanding the reasons for the price of
medicines is the ﬁrst stage in developing medicine pricing
policies that would ensure the affordability of medicines.
In its World Health Report 2000, WHO has ranked
Malaysia at 31 among 191 countries for the performance in
overall health care and was recommended as a model to other
developing countries. One indicator, the ‘‘Health Adjusted
Life Expectancy’’ at birth, is comparable to that of indus-
trialized countries [3]. Malaysia has achieved this level by
using only a few percentage of its gross domestic product on
healthcare [4]. Government spending on health care was RM
(Malaysian ringgits) 1 billion (USD 1 ¼ RM 3.82) or 3.6% of
the national budget in 1983 and 3.8% in 2001 [5,6]. Russia,
even after spending 25% per person more than Malaysia on
health care, has reportedly not performed well as indicted by
low rankings in a number of indicators [7].
However, this stable health care system is now facing
challenges, and increasing health care expenditures on
medicines is one of them. In 1995 the government spent
more than RM 200 million to procure drugs in public
hospitals, which has now increased to RM 800 million
annually, but still, faces challenges of access [8,9]. High drug
prices could be one of the reasons for this budgetary burden,
as it has been an issue and public interest nongovernmental
organizations have been lobbying for decades to reduce high
medicine prices [10,11].
Malaysia practices a ‘‘free market economy’’ and a ‘‘price
deregulation system’’ in which manufacturers, distributors,
and retailers set medicine prices without government control.
In Malaysia, medicine prices have been reported to escalate
even faster than prices in the developed world, and are higher
than international prices, indicating high medical costs [12–
14]. Although the government provides free medicine in
public hospitals, in recent years there are reports that
patients are increasingly asked to buy their own medicines
[4,15]. Nonavailability of medicines and long waiting hours
are other reasons that patients obtain their medicines from
private pharmacies and dispensing doctors. A consumer
survey showed that 37% of patients obtain medicines from
private hospitals or clinics and 42% from retail pharmacies,
requiring signiﬁcant out-of-pocket expenditures [16].
With the annual increase in drug costs and high medicine
prices, the government is ﬁnding it increasingly hard to
ﬁnance pharmaceuticals in the public sector. To deal with
this budgetary burden, the government is planning to change
the current system of free drugs into a pay-per-fee system,
whereby private dispensaries in government hospitals will be
set up (initially in two public hospitals) to reduce the annual
subsidy cost. It is expected that the public may have to pay for
medicines obtained from government hospitals in future [9].
If patients are asked to purchase their medicine themselves,
the problem of affordability may worsen. In that scenario, the
out-of-pocket expenditures will rise further and will pose
serious challenges to public health.
To investigate these issues, a study to measure medicine
prices, price structure, availability, and affordability was
carried out in different sectors—in the public and the private
retail pharmacy sectors and in dispensing doctors’ clinics.
Prices were compared with IRPs.
Methods
The study followed the WHO–Health Action International
(HAI) methodology [1]. Among a total of 48 medicines
included in the survey, 28 belong to the core list medicines
suggested by WHO–HAI for international comparison, and
20 were added as supplementary drugs. The core list
medicines were selected on the basis of the global disease
burden. The supplementary list was prepared on the basis of
the local disease burden, local needs as determined by a
community survey, while other factors, such as drug
availability and utilization patterns, were taken into account
[17].
Drugs selected for the supplementary list had to have an
IRP. The supplementary list was ﬁnalized after expert
opinion and feedback from international experts (from
WHO and HAI) and a national advisory group (a group of
practicing pharmacists and doctors, an economist, academi-
cians, ofﬁcials from Ministry of Health, and a consumer
representative. All the medicines included in the study are
listed in Table S1.
For each medicine, data were collected on the price and
availability of: innovator brand (IB), most-sold generic
equivalent (MSG), and lowest-price generic equivalent
(LPG). The MSG was estimated nationally through prelimi-
nary surveys, while the LPG was determined at the facility
level.
A systematic sampling method was used to collect data.
Four geographical regions in West Malaysia were selected
including the Federal territory of Kuala Lumpur, Penang
(northwest), Johore Bahru (southeast) and Kota Bharu (north-
east). Areas 2–4 are within 400 kilometres (one day travelling)
from Kuala Lumpur (Area 1). These regions are fairly
representative of the whole country. In each area, one major
city and four peripheral cities were chosen. In each area, the
main government hospital in the major city and four other
government hospitals in peripheral cities were included. The
peripheral area was no more than a two-hour drive from the
major city selected. One dispensing doctor and one or two
private retail pharmacies were chosen within a ﬁve-kilometre
radius of the index government hospital. The distribution
and the number of all facilities sampled are listed in Table 1.
An online map of Malaysia containing the areas mentioned in
Table 1 is available on Wikimapia (http://wikimapia.org/
#y¼3255693&x¼101700439&z¼8&l¼0&m¼a&v¼2). Data collec-
tion was undertaken by pharmacy students, the associate
survey manager, and the principal investigator.
For the purpose of statistical analysis, the drugs found
common in all four regions were included. ‘‘Median unit
price’’ for each medicine was calculated and then the
‘‘median-median’’ among the four regions for matched sets
of medicines was compared. A Kruskal-Wallis test was
applied, and p , 0.05 was used to indicate a signiﬁcant
difference.
Medicine prices and availability were assessed in public
sector facilities, community retail pharmacies, and dispensing
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unit prices were calculated, and each entry on the form was
checked carefully on the day of data collection. The data
collected on the medicine price data collection form were
entered by designated personnel into the software Interna-
tional Medicines Price Workbook (v. 3.06). The prices were
double entered to ensure accuracy. The Workbook’s auto
checker was also used to assist in the veriﬁcation process.
The Workbook software calculated the median price ratio
(MPR) for each medicine type in each sector only if the
medicine was available in at least four facilities. The MPR was
the comparison of the local median unit price of the
medicine with the median unit price in the Management
Sciences for Health 2003 Price Indicator Guide (the IRP) [18].
The IRPs are the medians of recent procurement or tender
prices offered by predominantly not-for-proﬁt suppliers to
developing countries for multi-source products [18]. Nor-
mally, an MPR of 1 or less is taken as efﬁcient procurement in
the public sector, while below 3 is considered efﬁcient for the
private sector [19].
To assess affordability, ten common diseases in Malaysia
were selected. The affordability was computed using the daily
wage of the lowest-paid unskilled government worker, which
has been assessed as RM 16.03 per day (USD 4.18).
Medicine component costs were also recorded in the
public, private, retail pharmacy and dispensing doctors’
sectors in Kuala-Lumpur to assess pricing structure. For this,
a separate form was developed and validated. Five medi-
cines—atenolol 50 mg tablet (IB), atenolol 50 mg (generic),
losartan 50 mg (IB), omeprazole 20 mg tablet (IB), and
omeprazole 20 mg (generic)—were chosen on the basis of
their widespread use and availability. The WHO–HAI
methodology was followed to collect data on the different
stages in the distribution chain [20]. Stage 0 of the component
cost is manufacturer’s selling price (MSP). Stage 1 includes
stage 0 and insurance and freight. Stage 2 includes customs
charges, port charges, and quarantine charges after the
arrival of medicines in the country. It also includes ﬁnance,
banking fees, and transport charges. Letter of credit charges
are included in the ﬁnance and banking fees. Stage 3 includes
distributors’ and/or wholesalers’ charges. Stage 4 is retailers’
and dispensing doctors’ markups. Stage 5 is composed of the
value added tax and goods and services tax. As there are no
value added tax, goods and services tax, or dispensing fees in
Malaysia, data for stage 5 could not be collected. Data
collection started with the patient/retail price; all the fees
collected and the costs were deducted until a cost approx-
imating the MSP was arrived at. All data on price components
were collected in the Kuala Lumpur area of Malaysia. A
description of the component cost stage by stage is given in
Table S2.
Results
In this study, 20 public hospitals, 32 private sector
pharmacies, and 20 dispensing doctors’ clinics were selected
for data collection.
Medicine Prices
In procurement for the public sector, the MPRs of 14 IBs
were 2.41 times the IRPs, while for 26 MSG and LPG products,
median MPRs were 1.56 and 1.09 times the IRP, respectively.
The MPRs of four IBs—ﬂuoxetine, loratadine, amlodipine,
and simvastatin—were more than ten times the IRP. In
private sector retail pharmacies (PSRPs), the median MPR for
32 IBs was 16.35 times the IRP, while the generics had median
MPRs of 6.89 for 31 MSGs and 6.57 for 36 LPGs. The MPRs for
four IBs in the private sector were over 50 (ﬂuconazole,
ciproﬂoxacin, furosemide, ﬂuoxetine) with generic MPRs
ranging from 10.9 to 39.3 for these four medicines. In the
dispensing doctor sector (DDS) the median for the 17 IBs was
15.40 times the IRPs, while both the MSGs and LPGs were 7.76
times higher than the international reference prices. Some of
the generics, such as metformin, hydrochlorothiazide, and
isosorbide dinitrate were twice the price in dispensing
doctors’ clinics that they were in PSRPs. Table 2 summarizes
the median MPRs of all the sectors studied.
Large variations in MPRs over the four geographical areas
in private sector retail pharmacies were noted. The highest
number of pharmacies were located in Federal Territory
(Kuala Lumpur), followed by Johore Bahru, Penang, and Kota
Bharu. Of all the drugs, the highest median MPR for IBs
Table 2. Median MPRs of IBs, MSGs, and LPGs in Public
Procurement Sector, Private Sector Retail Pharmacies, and
Dispensing Doctors’ Sector
Drugs Public
Sector
Private Sector
Retail Pharmacies
Dispensing
Doctor Sector
IBs 2.41 16.35 15.40
MSGs 1.56 6.89 7.76
LPGs 1.09 6.57 7.76
doi:10.1371/journal.pmed.0040082.t002
Table 1. Distribution and Number of Facilities for Sampling Plan
Area General
Hospital
Private
Pharmacies
a
Dispensing
Doctors
a
Kuala Lumpur 12 1
Klang 1 2 1
Kajang 1 2 1
Banting 1 1 1
Sg Buloh 1 1 1
Johore Bahru 12 1
Muar 1 2 1
Segamat 1 2 1
Kluang 1 1 1
Kulai 1 1 1
Penang 12 1
Seberang Jaya 1 2 1
Bukit Mertajam 1 2 1
Balik Pulau 1 1 1
Kepala Batas 1 1 1
Kota Bharu 12 1
Gua Musang 1 2 1
Tumpat 1 2 1
Pasir Puteh 1 1 1
Pasir Mas 1 1 1
Total 20 32 20
aWithin 5 km of general hospital
doi:10.1371/journal.pmed.0040082.t001
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(18.76), Johore Bahru (17.76), and Penang (15.82) (Figure 1).
Price comparisons were made only when drugs were found
to be commonly available in all four regions. Thus, while 144
drugs were available overall, only 77 were common in every
region. Kruskal-Wallis test indicated a nonsigniﬁcant (p ¼
0.748) difference in the prices of above 77 drugs (Table 3).
The price variation in pharmacies appeared to have little
linkage with the density of pharmacies, with the exception of
Kota Bharu, where the number of pharmacies is the lowest
but the drug costs are highest. Another reason for the highest
prices could be distance: this state is far from Kuala Lumpur,
the main distribution hub for pharmaceuticals. However, for
the other states, the reasons for price differentials could not
be determined with certainty; the only possible reason could
be a ‘‘free price-setting’’ environment.
The MPR of IB amlodipine showed the highest variation,
followed by that of IB glibenclamide and MSG ciproﬂoxacin.
The MPR of metformin varied considerably; it was 3.9 times
the IRP in Kuala Lumpur, 4.2 times in Johore Bahru, 3.4 times
in Penang and 4.9 times (the highest) in Kota Bharu.
Availability
In the public sector, median availability was very low, and
only 25% of the generic drugs were available. In the private
pharmacies, the median availability of all surveyed medicines
was 43% for LPG, 18% for MSGs, and 39% for IBs. In
dispensing doctors’ clinics, the availability was 45% for LPGs,
15% for MSGs, and 10% for IBs.
The availability was also found low on the drugs, which are
listed in the National Essential Drug List and the Drug
Formulary of Malaysia [21,22]. For 41 medicines that were
found in both sources, a combined analysis show that in the
public sector, median availability was 40% for LPGs, 0% for
MSGs, and 5% for IBs. In private sector retail pharmacies,
median availability was 43.8% for lowest price generics,
18.8% for most sold generics and 40.6% for IBs. In the DDS,
median availability was 45% for LPGs, 10% for MSGs, and
10% for IBs.
Low availability of antiviral drugs such as indinavir,
nevirapine, and zidovudine was found in public hospitals,
private pharmacies, and dispensing doctors’ clinics. No
private retail pharmacy was found to carry any version of
diazepam 5 mg tablets or ﬂuphenazine 25 mg/ml injection.
Availability data can be found in Table 4.
Affordability
As medicines are provided free in the public sector,
affordability has been assessed only for the private sector. A
one-month treatment of IB ranitidine (150 mg twice daily) for
peptic ulcer required 7.5 days’ wages when purchased from
private pharmacies and 8 days’ wages from dispensing
doctors’ clinics. The cost of generic versions of ranitidine
was 3 days’ wages in the pharmacies and 3.7 days’ wages from
the dispensing doctors’ clinics. IB omeprazole (20 mg daily)
cost 14–15 days’ wages for a one-month treatment, while its
LPG cost about 3–4 days’ wages in both sectors. The cost of a
one-month treatment with IB amlodipine (5 mg daily)
required about 4.9 days’ wages. To buy simvastatin (20 mg
daily), the patient had to pay 7.5 days’ wages in private
pharmacies and 6 days’ in dispensing doctors’ clinics.
Purchasing generic simvastatin cost about 2.3 days’ wages in
both sectors.
Fluoxetine (20 mg daily) cost about 26 days’ wages for one
month of treatment when purchased at private pharmacies.
IB acyclovir for acute viral infections (200 mg ﬁves time daily
for 5 days) cost patients 8 days’ wages, while generic cost 3
days’ wages. Patients have to pay 2 days’ salary to buy the IB
glibenclamide, while for generic products they have to spend
approximately half a day’s salary. Figure 2 shows the
affordability data in the DDS and PSRP for selected drugs.
Price Components
Procurement for public sector. Generic atenolol in stage 1
(MSP þ insurance and freight) was found to be 68% of the
total cost while it was 79% for IB atenolol. The total markups
(in all stages) for atenolol were 47%and 27%, respectively, for
its generic and IB. For generic omeprazole stage 1 con-
tributed 81% while the total markups were 26%. For IB
omeprazole, stage 1 was 84% and the markups were 18%. For
losartan the stage 1 component price was 83%, while total
markups were 20% (Table 5).
Figure 1. Regional Variation in Median MPRs in Private Retail Sector
Pharmacies
doi:10.1371/journal.pmed.0040082.g001
Table 3. Mean Prices (RM) and Variances of the 77 Drugs
Common in All Four Regions
Regions Mean Standard Deviation Standard Error
Kuala Lumpur 2.19 4.68 0.53
Johore Bahru 2.09 4.55 0.52
Penang 1.95 4.16 0.47
Kota Bharu 2.22 4.37 0.50
For the purpose of statistical analysis, the drugs that were common in all four regions
were included in the analysis (i.e., although there were total 144 drugs total, 77 were
common in all four regions). ‘‘Median unit price’’ for each medicine was calculated, and
then the ‘‘median-median’’ among the four regions for matched sets of medicines was
compared. A Kruskal-Wallis test was applied and p , 0.05 was taken as significant
difference. SD and SE were measured for the same set (77) of medicines.
doi:10.1371/journal.pmed.0040082.t003
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atenolol were 150% with stage 1 being only 40% of the ﬁnal
price. For IB atenolol, the markups were 80%, with the base
price 56% of the ﬁnal cost. For generic and IB omeprazole,
the markups were 147% and 83% and stage 1 was 41% and
56%, respectively. For losartan, stage 1 was 61% and markups
were 65% (Table 5).
Dispensing doctors’ sector. In the DDS, stage 1 was 30% for
generic atenolol and 43% for IB atenolol. The markups of
atenolol were 234% and 129% for generic and IB, respec-
tively. For IB omeprazole, stage 1 was 53% of the ﬁnal cost
and the markups were 90%. For generic omeprazole, stage 1
was 24% and total markups were 329% (Table 5). As
indicated in Table 6, for generic omeprazole, the manufac-
turing price for a pack of 30 capsules was 29.96 RM, and after
the addition of a 3% local transport cost, it became 30.86 RM;
it jumped to 128.57 RM with a retailer mark up of 316%. For
IB losartan, stage 1 was 51% and markups were 94% (Table
5).
Discussion
In Malaysia, public sector procurement prices were high
for IBs, and both IBs and generics were very expensive in
DDSs and PSRPs when compared with the IRPs. Prices varied
across sectors in private sector retail pharmacies.
Malaysian medicine prices were very high in terms of
international pricing (the IRP). The Malaysian dataset was
also compared with India and Sri Lanka as these countries
have shown efﬁcient procurement and pricing. In Indian
state of West Bengal, in public procurement sector, a median
MPR of 0.75 has been reported for generics while in private
retail pharmacies a median MPR of 2.86 and 2.17 has been
observed for IBs and LPGs, respectively [23]. In the Indian
state of Rajasthan, for generic medicines a median MPR of
0.96 was noted in the public procurement sector, while in
PSRPs median MPRs of 2.81 and 1.83 were recorded for IBs
and LPGs, respectively [24]. A similar situation was found in
Sri Lanka, where a median MPR of 2.67 was noted for IBs and
0.82 for LPGs in PSRPs [25].
Low availability of medicines on the National Essential
Drug List and the Drug Formulary [21,22] were found in all
sectors, particularly in the public sector. Poor availability of
g e n e r i c sw a sa l s os e e ni nt h ep u b l i cs e c t o r .T h el o w
availability of medicines at public hospitals could have direct
implications on access, as patients are then forced to buy
these medicines from private pharmacies or dispensing
doctor clinics. Private pharmacies carried fewer generic
Table 4. Median Percentage Availability of Selected Medicines in the Public Sector, Private Retail Pharmacy Sector, and Dispensing
Doctors’ Sector
Medicine and Dose IB MSG LPG
Public Sector
(n ¼ 20)
PSRPs
(n ¼ 32)
DDS
(n ¼ 20)
Public Sector
(n ¼ 20)
PSRPs
(n ¼ 32)
DDS
(n ¼ 20)
Public Sector
(n ¼ 20)
PSRPs
(n ¼ 32)
DDS
(n ¼ 20)
Allopurinol 100 mg tab 0.0 46.0 10.0 10.0 31.0 35.0 10.0 68.0 80.0
Amitriptyline 25 mg tab 0.0 6.0 0.0 70.0 40.0 35.0 70.0 43.0 50.0
Amlodipine 5 mg tab 70.0 87.0 70.0 0.0 0.0 0.0 0.0 0.0 0.0
Amoxicillin–clavulanic acid
(500þ125) mg
0.0 81.3 30.0 0.0 9.4 35.0 0.0 43.8 45.0
Beclomethasone 50 lg/dose inhaler 15.0 18.0 10.0 0.0 3.0 0.0 0.0 18.0 15.0
Cotrimoxazole suspension
(8þ40) mg/ml
0.0 0.0 20.0 0.0 0.0 0.0 25.0 3.1 30.0
Diazepam 5 mg 15.0 0.0 0.0 55.0 0.0 30.0 55.0 0.0 50.0
Doxycycline 100 mg cap 0.0 6.0 5.0 0.0 25.0 15.0 90.0 68.0 85.0
Erythromycin 250 mg caps/tab 0.0 18.0 0.0 0.0 15.0 25.0 35.0 50.0 65.0
Enalapril 10 mg tab 10.0 75.0 20.0 60.0 25.0 0.0 65.0 34.0 45.0
Fluoxetine 20 mg 85.0 31.3 5.0 0.0 0.0 0.0 0.0 0.0 0.0
Fluphenazine injection 25 mg/ml 0.0 0.0 0.0 0.0 0.0 10.0 70.0 0.0 10.0
Furosemide 40 mg 0.0 37.5 20.0 100 12.5 5.0 100 81.3 70.0
Hydrochlorothiazide 25 mg 0.0 0.0 5.0 0.0 40.6 20.0 0.0 46.9 35.0
Indinavir 400 mg 40.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Lovastatin 20 mg 0.0 3.1 0.0 100 68.8 35.0 100 84.4 50.0
Metformin 500 mg 0.0 84.4 15.0 0.0 62.5 15.0 90.0 87.5 90.0
Nevirapine 200 mg 0.0 0.0 0.0 0.0 0.0 0.0 25.0 0.0 0.0
Nifedipine retard 20 mg 0.0 15.6 10.0 0.0 59.4 35.0 0.0 68.8 45.0
Phenytoin 100 mg 80.0 43.8 10.0 0.0 6.3 20.0 0.0 12.5 25.0
Prazosin 1 mg 90.0 50.0 20.0 0.0 18.8 5.0 0.0 25.0 20.0
Propranolol 40 mg 0.0 59.4 30.0 0.0 28.1 5.0 90.0 68.8 55.0
Pyrimethamine–sulfadoxine
(25þ500) mg
5.0 0.0 0.0 0.0 3.1 0.0 35.0 3.1 5.0
Ranitidine 150 mg 0.0 84.4 30.0 100 90.6 30.0 100 93.8 55.0
Salbutamol inhaler 0.1 mg/dose 0.0 84.4 45.0 0.0 93.8 15.0 80.0 96.9 35.0
Simvastatin 20 mg 90.0 81.3 20.0 0.0 43.8 20.0 0.0 68.8 65.0
Valproic acid 200mg 85.0 56.3 10.0 0.0 0.0 0.0 0.0 0.0 0.0
Zidovudine 100 mg 25.0 0.0 0.0 40.0 0.0 0.0 40.0 0.0 0.0
doi:10.1371/journal.pmed.0040082.t004
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Evaluating Drug Pricesdrugs than did the dispensing doctors, and thus they may
dispense more IBs. Due to nonavailability of many drugs,
many patients now dig deep into their pockets to pay for
medicines [26]. Better availability in the public sector would
put pressure on private sector to lower generic prices.
Dispensing doctors tend to prescribe generics, but they
charge excessive markups for generics compared to IBs.
Psychotropics such as diazepam and ﬂuphenazine were not
found in any of the retail pharmacies, probably due to the
stricter regulatory requirements of their drug licences.
However, these medicines were available at dispensing
doctors’ clinics and public facilities. Generic versions of
ﬂuoxetine and amlodipine were not available in the market,
as these drugs are still under patent in Malaysia.
Affordability data indicated that a large part of the
population would not be able to pay for their medicines.
Some diseases such as cardiovascular disorders are on the rise
in Malaysia [27]. Some common drugs to treat these
conditions are amlodipine and simvastatin, and patients have
to pay between 5–7 days’ wages to buy one month’s treatment
with these drugs. Mental illness has become the fourth leading
cause of morbidity in the country, but medicines such as
ﬂuoxetine cost about 26 days’ wages for one month’s
treatment, and there is no generic version available for this
medicine. To treat common diseases such as diabetes and
viral illnesses, patients have to pay 2 days’ and 8 days’ wages to
buy the innovator versions of glibenclamide and aciclovir,
respectively.
Affordability of generics also seems to be an issue in the
DDS and PSRP. To be able to purchase generic aciclovir and
simvastatin, patients have to work for 2 to 3 days. The
unaffordability of these medicines could pose problems for
public health.
Price Components
Add-on costs had a substantial impact on medicine prices
in all sectors in Malaysia. In retail pharmacies, actual markups
of 100%–140% were found for generics, and 25%–38% for
innovators.
The Malaysian markups were compared with those in other
countries where the WHO–HAI surveys have been published,
and found to be higher in Malaysia. For example, in Sri
Lanka’s private for-proﬁt pharmacy sector, the wholesale
markup is 8% and retailer’s markup is 16%. In Kenya, the
private retail sector (for imported medicine) has a wholesale
markup of 15%–30% and a maximum retailer markup of
20%–33%. In Peru, for imported generic medicine the
distributor’s markup is 36% while the retailer’s markup is
33%. Armenia’s private sector (for imported medicines)
wholesaler/distributor markup ranges from 18% to 25%
while the retailer’s markup is 15%–25%. In Brazil, in the
private retail sector the wholesaler’s and retailer’s markup is
around 27%. In the Philippines’ private retail sector, the
distributor and retailer markup for IBs is 30%, and for locally
manufactured generics the retailer’s markup is about 100%
[28]. In the Indian state of Maharashtra, a proﬁt margin of
20% was found for generic atenolol [29] compared to 100%
in Malaysia.
Add-on costs for both IBs and generic equivalents were
higher in the DDS than the other two sectors. For IBs
dispensing doctors’ markups ranged from 50% to 76%, while
for generics they were up to 316% (generic omeprazole). In
the Malaysian health care system, patients rely heavily on
physicians’ advice and recommendations. Proﬁt margins and
markups in this sector are particularly high for generics as
compared to IBs.
Generally, high markups along the supply chain drive up
prices and make medicines less affordable; therefore prices of
medicines can be lowered substantially by reducing the
markups.
Dispensing doctors are taking advantage of lower priced
generics and are marking them up to make a larger proﬁt.
Some generics, such as atenolol, were still less expensive than
their innovator and even after a signiﬁcant markup leave
them considerably more affordable—than the IB. However,
for generic omeprazole markups were found to be excessive.
This trend of increased proﬁts could lead to irrational drug
use, as has been observed in Zimbabwe, where a desire to
increase income was associated with less clinically and
economically appropriate prescribing [30].
Components analysis indicated high MPRs on the costliest
IBs, principally reﬂecting high manufacturers’ prices. The IB
prices remain unaffected even in the presence of generic
competition because they are being sold with progressive
proﬁts to the manufacturers, distributors, and retailers.
Generics are more affordable than IBs, and they could be
even more so if markups were restricted and there were
incentives to encourage increased use of generics.
Economic Analysis
Medicine price determination is a complex process, and
most national markets are highly segmented with different
procedures applying in different sectors and to different
medicines. ‘‘Free markets’’ do not apply with medicines
under patent, as these by deﬁnition confer a degree of market
exclusivity to the manufacturer. Manufacturers frequently set
different prices in different markets even within the same
country. In Malaysia, for IB medicines, generally the
conditions for a properly functioning market are not met,
as there is a supplier monopoly for these particular
medicines. The actual situation in Malaysia differs from
sector to sector as well as by type of medicine. Branded
generics, the most numerous generics, are more akin to other
Figure 2. Affordability of Standard Treatments in the Dispensing
Doctors’ Sector and Private Sector Retail Pharmacies
doi:10.1371/journal.pmed.0040082.g002
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Evaluating Drug Pricesbranded commodities, in that they compete with each other
and are therefore subject to normal supply and demand
pressures in determining their prices.
The higher markups on generics observed in the compo-
nents analysis suggest that the prices of innovator drugs are
used as a limit to generic pricing. In such a situation, price-
controlled generics may be a sensible way out of the problem.
Malaysia has no history of price control on retail medicines,
and indeed the current commercial ethos of the country is
toward market mechanisms. Recent research suggests that
increasing the available choices of generics on the market
does not, on its own, bring down prices [17]. Nevertheless,
printed maximum retail prices on packs of selected generic
medicines (as in India), under the oversight of the Pharma-
ceutical Services Division of the Ministry of Health, could be
used as a mechanism to ensure that retail prices do not
diverge excessively from IRPs. In the process, this would put
downward pressure on other generic prices and on the prices
of IBs (by raising the price differential or ‘‘brand premium’’).
Overall high prices in Malaysia, compared to the reference
prices, might be due to a relatively unregulated system
[31,32]. The Malaysian government is encouraging the
pharmaceutical industry to grow, but the degree to which
the market should be allowed to determine drug prices is a
problematic issue [33]. Nevertheless, the growing burden of
medicine spending on poorer households cannot be ignored,
nor can costly medicines be dismissed as a problem of
inappropriate prescribing when retail generics from private
sector prescribers cost six to eight times international bulk
purchase prices. Any scheme of differential pricing should
recognize this, and purchasing bodies in Malaysia might make
effective use of such evidence in their discussion on pricing
with suppliers.
Pricing Models in Other Countries
Therefore, government involvement in pharmaceutical
pricing practices is necessary because leaving the ﬁnancing
and supply of drugs entirely to the market economy may also
fail to achieve public health objectives [2]. Pricing regulations
can be found in most of the European and Middle Eastern
countries, Australia, New Zealand, the Far East, and Canada
[34]. Some countries, such as France and Italy, regulate drug
prices directly through price control; others, such as
Australia, use pharmacoeconomic analyses and reference
pricing to determine the prices of drugs subsidized by the
government [35,36]. Australia and the province of Ontario in
Canada were also the ﬁrst to include cost effectiveness data in
decisions about reimbursement [37].
Germany and Japan control prices indirectly through limits
on reimbursement under social insurance schemes [35]. In
the UK, the National Pharmaceutical Pricing Authority
monitors prices through the Pharmaceutical Price Regulation
Scheme, which controls the prices of branded prescription
medicines to the National Health Service by regulating the
proﬁts that companies can make on sales [38]. In The
Netherlands, the government introduced reference-pricing
system in 1991, and wholesalers were forced to lower their
prices by an average of 20% in 1996 [39]. In Finland, the
application of marketing authorization must contain a
detailed assessment of cost of the drug therapy and the
prices of medicines [40]. Pricing regulations also seem vital, as
in many Latin American countries ‘‘free schemes of drug
prices’’ have not proved effective as a cost containment
mechanism. In Guatemala and Peru, prices have increased
over and above the exchange rate or the consumer price
index, and in Bolivia the practice of the free market concept
has not yielded any beneﬁts [41].
In India, essential drugs cannot cost more than twice the
cost of production, and the maximum retail price and local
taxes must be included in a drug’s ﬁnal printed price [42].
This model follows the ‘‘cost-plus pricing’’ where the prices
are negotiated between the manufacturer and the national
authority, based on raw material costs, production costs,
Table 5. Summary and Markups for Different Drugs in Public Sector, PSRPs, and DDS
Sectors Variable Atenolol 50 mg Tablet Omeprazole 20 mg Capsule Losartan 50 mg Tablet
Generic Innovator Generic Innovator Innovator
Public sector MSP 0.24 27.75 41.80 114.49 40.55
I&F 7.54 5.88
a 2.94 4.46
Total stage 1 7.78 33.63 41.80 117.43 45.01
Stage 5
(final price)
11.40 42.60 51.66 139.20 54.00
% Markup 46.5 26.7 25. 75 18.53 19.97
PSRPs MSP 2.08 34.17 31.20 126.47 51.10
I&F 7.54 5.88
a 2.91 4.46
Total stage 1 9.62 40.05 31.20 129.38 55.56
Stage 5 (final price) 24.00 72.00 77.14 237.00 91.50
% Markup 149.48 79.77 147.24 83.1 64.68
DDS MSP 2.04 35.29 29.96 132.37 52.05
I&F 7.54 5.88
a 2.94 4.46
Total stage 1 9.58 41.17 29.96 135.31 56.51
Final price 32.00 94.29 128.57 257.14 110.00
% Markup 234 129.02 329.13 90.03 94.65
Markups calculated as (final price – stage 1)/stage 1. Atenolol pack size, 60 tablets; losartan pack size, 30 tablets; omeprazole pack size, 30 capsules.
aInsurance & freight for generic omeprazole are included in the local transport. Local transport is at stage 2 and 3% (amount is RM 0.90) of the final cost.
I&F, insurance and freight.
doi:10.1371/journal.pmed.0040082.t005
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Evaluating Drug Pricesmarketing costs, and a reasonable allowance for proﬁt [2].
The Canadian Patented Medicines Prices Review Board sets
maximum introductory prices for newly patented medica-
tions, and forecasts and regulates the prices of medicines by
calculating a consumer price index adjustment factor [43,44].
However, Malaysia, a middle-income developing country,
so far practices none of the pricing methods mentioned
above. Price controls can also be implemented in a variety of
ways, some of which cause less distortion in the medicines
market than others. Perhaps the most efﬁcient and effective is
to use, in purchasing, price benchmarks in countries at
comparable economic levels, to ensure that a country is not
becoming a ‘‘high price island.’’ Reference pricing sets or
limits the price of an individual drug by comparison with the
price of other drugs in other countries [2].
Access to affordable and lower priced medicines are the
aims of Draft National Medicine Policy of Malaysia, but
according to this study’s ﬁndings, these aims are not being
achieved [45]. A medicine pricing policy and a price
monitoring system is required in Malaysia. Prices may also
be controlled by ﬁxing margins of retailers and wholesalers,
and enforced by marking maximum prices on packs. On the
procurement side, a gallery of price-reducing strategies, from
bulk purchasing, evidence-based negotiation based on cost-
effectiveness, parallel trading, or differential pricing may be
employed to put downward price pressure on manufacturers.
There must be incentives to promote the use of generics, and
some form of mandatory generic substitution is also required.
Limitations of the Study
Some of the drugs studied, such as ﬂuconazole, amox-
icillin–clavulanic acid, captopril, ciproﬂoxacin, nifedipine
retard, and zidovudine were found in different strengths
from what were speciﬁed in the medicine price data
collection form. As a result, they were not recorded. There-
fore, nonavailability and lower availability of these drugs may
not be meaningful, because they may be available but in a
different strength.
Also, in the public sector, availability of drugs was low
overall, and moreover the drugs, which were available only in
four or more facilities, were included in the analysis.
Therefore, low availability of drugs in the public sector also
makes the median MPR less robust.
Conclusion and Recommendations
Expecting an unregulated and free market system to ensure
access to essential medicines in Malaysia seems unrealistic.
Prices were found to be generally high in PSRPs and
dispensing doctor clinics, for IBs as well as generics. In the
public sector availability was low even for the medicines on
the National Essential Drugs List. Low affordability was
observed even for the drugs use for some common ailments,
such as hypertension, asthma, respiratory disorders. Gener-
ally high markups and proﬁt margins were noted in
dispensing doctors and private retail sectors for generics
and IBs. The MSP was high for innovator brands as compared
to their generics in all sectors.
A pricing policy is needed, and it should be incorporated
into the national drug policy. This policy should aim to
improve the availability of affordable generics. A package of
measures, some of them incremental or experimental,
suggests itself on the basis of the above ﬁndings. Such
measures would include ensuring better availability in the
public sector, either by better targeting of existing public
spending for medicines on priority medicines, or by increas-
ing the public budget for essential medicines; this in turn
would put downward pressure on private sector generic
prices. The package would also review purchasing practices to
ensure greater efﬁciency. And although dispensing doctors
may be useful as prescribers of generic drugs, they have
incentives to overcharge because of the high cost of IB
medicines. Reducing the brand premium by better purchas-
ing strategies and by experimenting with the control of
selected generic prices could be other options.
A price monitoring system is also needed in Malaysia. The
availability of HIV drugs must also be ensured. A generic
policy should also be devised that should include campaigns
to promote generics, increase consumer awareness, and
introduce incentives for pharmacists and doctors to prescribe
and dispense generics.
Supporting Information
Table S1. Drugs Surveyed in This Study
(A) List of the core drugs surveyed.
(B) List of supplementary drugs surveyed.
Found at doi:10.1371/journal.pmed.0040082.st001 (49 KB DOC).
Table S2. General Overview of Component Costs by Stages
Found at doi:10.1371/journal.pmed.0040082.st002 (53 KB DOC).
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Evaluating Drug PricesEditors’ Summary
Background. The World Health Organization has said that one-third of
the people of the world cannot access the medicines they need. An
important reason for this problem is that prices are often too high for
people or government-funded health systems to afford. In developing
countries, most people who need medicines have to pay for them out of
their own pockets. Where the cost of drugs is covered by health systems,
spending on medicines is a major part of the total healthcare budget.
Governments use a variety of approaches to try to control the cost of
drugs and make sure that essential medicines are affordable and not
overpriced. According to the theory of ‘‘free market economics,’’ the
costs of goods and services are determined by interactions between
buyers and sellers and not by government intervention. However, free
market economics does not work well at containing the costs of
medicines, particularly new medicines, because new medicines are
protected by patent law, which legally prevents others from making,
using, or selling the medicine for a particular period of time. Therefore,
without government intervention, there is nothing to help to push down
prices.
Why Was This Study Done? Malaysia is a middle-income country with a
relatively effective public health system, but it is facing a rapid rise in
drug costs. In Malaysia, medicine prices are determined by free-market
economics, without any control by government. Government hospitals
are expected to provide drugs free, but a substantial proportion of
medicines are paid for by patients who buy them directly from private
pharmacies or prescribing doctors. There is evidence that Malaysian
patients have difficulties accessing the drugs they need and that cost is
an important factor. Therefore, the researchers who wrote this paper
wanted to examine the cost of different medicines in Malaysia, and their
availability and affordability from different sources.
What Did the Researchers Do and Find? In this research project, 48
drugs were studied, of which 28 were part of a ‘‘core list’’ identified by
the World Health Organization as ‘‘essential drugs’’ on the basis of the
global burden of disease. The remaining 20 reflected health care needs
in Malaysia itself. The costs of each medicine were collected from
government hospitals, private pharmacies, and dispensing doctors in
four different regions of Malaysia. Data were collected for the ‘‘innovator
brand’’ (made by the original patent holder) and for ‘‘generic’’ brands
(an equivalent drug to the innovator brand, produced by a different
company once the innovator brand no longer has an exclusive patent).
The medicine prices were compared against international reference
prices (IRP), which are the average prices offered by not-for-profit drug
companies to developing countries. Finally, the researchers also
compared the cost of the drugs with daily wages, in order to work out
their ‘‘affordability.’’
The researchers found that, irrespective of the source of medicines,
prices were on average very much higher than the international
reference price, ranging from 2.4 times the IRP for innovator brands
accessed through public hospitals, to 16 times the IRP for innovator
brands accessed through private pharmacies. The availability of
medicines was also very poor, with only 25% of generic medicines
available on average through the public sector. The affordability of many
of the medicines studied was again very poor. For example, one month’s
supply of ranitidine (a drug for stomach ulcers) was equivalent to around
three days’ wages for a low-paid government worker, and one month’s
supply of fluoxetine (an antidepressant) would cost around 26 days’
wages.
What Do These Findings Mean? These results show that essential drugs
are very expensive in Malaysia and are not universally available. Many
people would not be able to pay for essential medicines. The cost of
medicines in Malaysia seems to be much higher than in areas of India
and Sri Lanka, although the researchers did not attempt to collect data in
order to carry out an international comparison. It is possible that the
high cost and low availability in Malaysia are the result of a lack of
government regulation. Overall, the findings suggest that the govern-
ment should set up mechanisms to prevent drug manufacturers from
increasing prices too much and thus ensure greater access to essential
medicines.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040082.
  Read a related PLoS Medicine Perspective article by Suzanne Hill
  Information is available from the World Health Organization on
Improving Access to Medicines
  Information on medicine prices is available from Health Action
International
  Wikipedia has an entry on Patent (a type of intellectual property that is
normally used to prevent other companies from selling a newly
invented medicine). (Wikipedia is an internet encyclopedia anyone can
edit.)
  The Drugs for Neglected Diseases Initiative is an international
collaboration between public organizations that aims to develop
drugs for people suffering from neglected diseases
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